Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

ProLynx Awarded NIH Grant to Develop Long-acting PTH Therapy

ProLynx has been awarded a small business innovation research grant from the National Institutes of Health (NIH) to develop its long-acting parathyroid hormone (PTH) therapy — known as PTH(1-34) — for people with hypoparathyroidism. Hypoparathyroidism is an uncommon condition characterized by low levels of PTH,…

Alizé Pharma 3 Rebrands as Amolyt Pharma, Plans AZP-3601 Trial

Alizé Pharma 3 is rebranding as Amolyt Pharma and plans to start clinical testing of a potential hypoparathyroidism treatment known as AZP-3601 later this year. “Our new name, Amolyt Pharma, is derived from ammolite, a rare gemstone originating from living organisms,” Thierry Abribat, PhD, the company’s founder and…

Calcific Tendonitis May Be Complication of Hypoparathyroidism

People with hypoparathyroidism may be at risk of having calcium crystals form in their tendons — a condition called calcific tendonitis — which can cause joint pain and inflammation, a new case report suggests. The report, “Acute calcific epicondylitis associated with primary hypoparathyroidism: a paradox effect…

Fahr’s, Disease Marked by Calcium Deposits in Brain, Traced to Thyroid Surgery in Case Study

A case report of a person diagnosed with Fahr’s disease related to post-thyroidectomy hypoparathyroidism highlights the importance of doing regular screening, including brain scans and blood tests, after this surgery. “Secondary Fahr’s Disease: A Consequence of Post-Thyroidectomy Hypoparathyroidism” was published in the European Journal of Case Reports…